MedTrace Logo

Implementation Study to Describe and Compare Retention Rate and Adherence to Adjuvant Therapy With Ribociclib With and Without Usage of Mobile Application in Patients With HR+ HER2-negative Stage II and III Breast Cancer in Real-world Practice

NCT06905301 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 240

Last updated 2026-05-05

No results posted yet for this study

Summary

This study is designed to evaluate the effect of using the application on the adherence of patients with luminal HER2- breast cancer (BC) stage II-III to adjuvant therapy with ribociclib in combination with an aromatase inhibitor (AI). The purpose of the app is to increase adherence to treatment by informing patients about the risks of relapse and adverse event prevention and treatment.

Conditions

Interventions

DRUG

Ribociclib

CDK4/6 inhibitor

DRUG

Letrozole

Aromatase inhibitor

DRUG

Anastrozole

Aromatase inhibitor

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-23
Primary Completion
2029-12-31
Completion
2029-12-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06905301 on ClinicalTrials.gov